Trials / Completed
CompletedNCT00587873
Sequential Administration of Oral 6-Thioguanine (6-TG) After Methotrexate (MTX) in Patients With Relapsed Hodgkin's Disease (Phase II)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to determine the incidence of complete and partial response and the duration of response in patients with recurrent or resistant Hodgkin's disease (HD) treated with sequential administration of oral 6-Thioguanin (6-TG) after IV Methotrexate (MTX).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Methotrexate | MTX 6mg/m2 given IV bolus, followed by 24mg/m2 given in 24hrs continuous infusion |
| DRUG | Leucovorin calcium | 5 mg orally at 12 hours after the end of MTX infusion then every 12 hrs for a total of 3 doses. |
| DRUG | 6-Thioguanine | 6-TG 300 mg/m2 PO as a single oral dose |
Timeline
- Start date
- 1994-03-01
- Primary completion
- 2003-12-01
- Completion
- 2009-06-01
- First posted
- 2008-01-08
- Last updated
- 2009-06-12
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00587873. Inclusion in this directory is not an endorsement.